All AbMole products are for research use only, cannot be used for human consumption.
WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. This agent is 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wildtype EGFR, than quinazoline-based EGFR inhibitors (HKI-272 and CL-387,785) in vitro. WZ4002 inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and WZ4002 prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002. In a 2-week efficacy study, WZ4002 treatment resulted in significant tumour regressions compared with vehicle alone in both T790M-containing murine models.
Clin Cancer Res. 2017 Oct 19; pii: clincanres.1577.2017.
Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM
WZ4002 purchased from AbMole
 |
Source | Clin Cancer Res (2017). Figure 4. WZ4002 (Abmole Bioscience) |
| Method | vitro observations | |
| Cell Lines | Mice harboring H1975 ER-TWIST+4-OHT tumors | |
| Concentrations | 25mg/kg | |
| Incubation Time | 5 d | |
| Results | "Consistent with our in vitro observations, while single-agent WZ4002 was sufficient to markedly slow the growth of the tumors, the addition of ABT-263 was necessary to shrink tumors (Fig. 4D)." |
 |
Source | Clin Cancer Res (2017). Figure 3. WZ4002 (Abmole Bioscience) |
| Method | Western blotting | |
| Cell Lines | H1975 parental cells (par), H1975 R1 cells (R1), and H1975 R2 cells (R2) | |
| Concentrations | 1 μM | |
| Incubation Time | 72 h | |
| Results | Similarly, in the H1975 EMT model induced by ER-TWIST, knockdown of ZEB1 led to de-repression of BIM protein and RNA (Fig. 3I and Sup. Fig. 5B, right panel) and restored EGFRi-induced apoptosis and re-sensitized these EMT cancers to WZ4002 (Fig. 3J and 3K). |
 |
Source | Clin Cancer Res (2017). Figure 2. WZ4002 (Abmole Bioscience) |
| Method | apoptosis quantified | |
| Cell Lines | HCC4006 and H1975 cells | |
| Concentrations | 1 μM | |
| Incubation Time | 72 h | |
| Results | We found directly inducing EMT by exogenous TWIST activation (Fig. 2) or chronic TGF- β treatment (Sup. Fig. 2) led to depressed levels of BIM resulting in suppression of EGFRi-induced apoptosis and resistance to EGFRi (WZ4002 and gefitinib). |
| Cell Experiment | |
|---|---|
| Cell lines | NSCLC or Ba/F3 cells |
| Preparation method | Cell proliferation and growth assays NSCLC or Ba/F3 cells were exposed to treatment for 72 hours and the number of cells used per experiment determined empirically and has been previously established2,7. All experimental points were set up in six to twelve wells and all experiments were repeated at least three times. The data was graphically displayed using GraphPad Prism version 5.0 for Windows, (GraphPad Software; www.graphpad.com). The curves were fitted using a non-linear regression model with a sigmoidal dose response. |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | EGFR-TL (T790M/L858R) mice and EGFR exon19 Deletion-T790M (TD) inducible bitransgenic mice |
| Formulation | NMP (10% 1-methyl-2-pyrrolidinone: 90% PEG-300) |
| Dosages | 25mg/kg daily |
| Administration | gavage |
| Molecular Weight | 494.97 |
| Formula | C25H27ClN6O3 |
| CAS Number | 1213269-23-8 |
| Solubility (25°C) | DMSO 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[4] Zhou W, et al. Nature. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
| Related EGFR/HER2 Products |
|---|
| Depatuxizumab
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. |
| Sevabertinib
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity. |
| BPIQ-I
BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. |
| HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. |
| SJF-1528
SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
